1. "2017"
Formats
  1. Journal Article (3053)
  2. Meeting Abstract (1581)
  3. Book Section (242)
  4. Conference Paper (35)
  5. Book Whole (12)
  6. Editorial (1)
  7. Review (1)
Groups
  1. Department of Medicine (2037)
  2. GSK Faculty (1130)
  3. Solid Tumor Oncology Division (1105)
  4. Sloan Kettering Institute Postdocs (1022)
  5. Surgery (893)
  6. Survivorship Research (780)

More Groups

People
  1. Sergio Giralt (86)
  2. Jose Baselga (68)
  3. Michael Berger (67)
  4. Monica Morrow (65)
  5. Jedd Wolchok (62)
  6. Martin Tallman (61)

More People

Years
  1. 2017 (4925)
Publications
  1. Journal of Clinical Oncology (349)
  2. Blood (233)
  3. Annals of Oncology (123)
  4. International Journal of Radiation Oncology, Biology, Physics (122)
  5. Modern Pathology (85)
  6. Laboratory Investigation (76)

More Publications

Publishers
  1. Elsevier Inc. (599)
  2. Springer (383)
  3. American Society of Clinical Oncology (378)
  4. Nature Publishing Group (310)
  5. Oxford University Press (280)
  6. American Society of Hematology (246)

More Publishers

Results (4925)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • National survey demonstrates practice gaps in cytogenetic and molecular testing in acute myeloid leukemia
    Meeting Abstract

    Altman, J. K.; Denzen, E.; Block, A. W.; Hasserjian, R. P.; Klepin, H.; Medeiros, B. C.; Noe, A.; Scales, W. E.; Tallman, M. S.; Wiley, K.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • TTI-621 (SIRPαFc), an immune checkpoint inhibitor blocking the CD47 "do not eat" signal, induces objective responses in patients with advanced, relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Ansell, S. M.; Flinn, I. W.; Maris, M. B.; O'Connor, O. A.; Lesokhin, A.; Advani, A. S.; Minden, M. D.; Percival, M. B. M.; Johnson, L. D. S.; Catalano, T.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Mutant ASXL1 cooperates with BAP1 to promote myeloid leukemogenesis
    Meeting Abstract

    Asada, S.; Goyama, S.; Inoue, D.; Takeda, R.; Kawazu, M.; Mano, H.; Kitamura, T.
    Blood (2017)

    Fulltext@MSK | Save
  • Next generation sequencing (NGS) based IGH and TCR clonality assays provide excellent specificity and sensitivity for routine clonal characterization and monitoring of lymphoproliferative disorders
    Meeting Abstract

    Arcila, M. E.; Syed, M.; Yu, W.; Kim, H.; Yao, J.; Ho, C.; Petrova-Drus, K.; Roshal, M.; Park, J. H.; Landgren, O.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • The damage sensory molecule TRPA1 positively regulates endogenous thymic regeneration after damage
    Meeting Abstract

    Argyropoulos, K.; Velardi, E.; Tsai, J.; Lazrak, A.; Jahn, L.; Dudakov, J. A.; van den Brink, M. R. M.
    Blood (2017)

    Fulltext@MSK | Save
  • Impact of PET staging of follicular lymphoma on treatment outcomes and prognosis
    Meeting Abstract

    Alperovich, A.; Batlevi, C. L.; Intlekofer, A. M.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, A. J.; Gerecitano, J.; Hamlin, P. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Ivosidenib or enasidenib combined with standard induction chemotherapy is well tolerated and active in patients with newly diagnosed AML with an IDH1 or IDH2 mutation: Initial results from a phase 1 trial
    Meeting Abstract

    Stein, E. M.; DiNardo, C. D.; Mims, A. S.; Savona, M. R.; Pratz, K.; Stein, A. S.; Fathi, A. T.; Stone, R. M.; Pollyea, D. A.; Odenike, O.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • High durable CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001): Defined composition allows for dose-finding and definition of pivotal cohort
    Meeting Abstract

    Abramson, J. S.; Palomba, M. L.; Gordon, L. I.; Lunning, M. A.; Arnason, J. E.; Wang, M.; Forero, A.; Maloney, D. G.; Albertson, T.; Garcia, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Ivosidenib (AG-120) in mutant IDH1 AML and advanced hematologic malignancies: Results of a phase 1 dose escalation and expansion study
    Meeting Abstract

    DiNardo, C. D.; De Botton, S.; Stein, E. M.; Roboz, G. J.; Mims, A. S.; Pollyea, D. A.; Swords, R. T.; Altman, J. K.; Collins, R. H.; Mannis, G. N.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-δ,γ inhibitor, in combination with romidepsin or bortezomib in relapsed/refractory T-cell lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Koch, R.; Mehta-Shah, N.; Myskowski, P.; Kheterpal, M.; Dogan, A.; Davey, T.; Galasso, N.; Evan, M.; Shah, M.; more...
    Blood (2017)

    Fulltext@MSK | Save